Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Pritesh J. Gandhi"'
Publikováno v:
Vascular Health and Risk Management, Vol Volume 2, Pp 39-48 (2006)
Matthew A Silva1, Jennifer L Donovan1,3, Pritesh J Gandhi2, Gregory A Volturo31Massachusetts College of Pharmacy and Health Sciences, Department of Pharmacy Practice, Worcester, MA, USA; 2Alexion Pharmaceuticals, Inc., Cheshire, CT, USA; 3UMass Memor
Externí odkaz:
https://doaj.org/article/48945f8535de4ab5a81863b25a5c8dc3
Autor:
Martha Arellano, Stefan Faderl, Roger M. Lyons, Harry P. Erba, Janice Gabrilove, David F. Claxton, Dirk Huebner, Tibor Kovacsovics, Pritesh J. Gandhi, Hagop M. Kantarjian
Publikováno v:
Leukemia & Lymphoma. 53:435-440
This report describes outpatient (OP) administration of clofarabine in older patients ( ≥ 60 years) with untreated acute myelogenous leukemia (AML). Overall, 112 patients underwent clofarabine induction. Clofarabine was administered to 35 OPs for a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fd89f20144ca85c618ad54a460cd1bb
https://doi.org/10.3109/10428194.2011.616960
https://doi.org/10.3109/10428194.2011.616960
Publikováno v:
Journal of Thrombosis and Thrombolysis. 22:139-150
Aspirin (ASA) and clopidogrel have been identified as standard of care in the prevention of major cardiovascular events. Aspirin irreversibly inhibits the cyclooxygenase-1 (COX-1) enzyme, whereas non-steroidal anti-inflammatory drugs (NSAIDs) reversi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::229dc4900a55f80c686c112ec709413b
https://doi.org/10.1007/s11239-006-8670-y
https://doi.org/10.1007/s11239-006-8670-y
Publikováno v:
Clinical Therapeutics. 28:26-35
The absolute frequencies of adverse events (AEs) between statins and placebo are very low in clinical trials, making clinical interpretation and application difficult.This meta-analysis was intended to synthesize the collective AE data observed in pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3ebdeb4e1c16efa279b90fd2133438e
https://doi.org/10.1016/j.clinthera.2006.01.005
https://doi.org/10.1016/j.clinthera.2006.01.005
Publikováno v:
Pharmacotherapy. 24:1793-1799
Four patients with severe burn injuries received enoxaparin 40 mg twice/day subcutaneously for the prophylaxis of venous thromboembolism (VTE). Peak antifactor Xa levels were measured 4 hours after administration of a dose, and trough antifactor Xa l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09c65aa5499440b6d4caa89ace02ce88
https://doi.org/10.1592/phco.24.17.1793.52344
https://doi.org/10.1592/phco.24.17.1793.52344
Autor:
Adams, David, Pritesh, J. Gandhi
Publikováno v:
In Revue Neurologique April 2019 175 Supplement 1:S129-S129
Publikováno v:
Journal of Thrombosis and Thrombolysis. 16:175-188
Ximelagatran, an oral direct thrombin inhibitor, has been investigated for the prevention and treatment of venous thromboembolism as well as for anticoagulation in atrial fibrillation. Unique properties of ximelagatran are that it is a prodrug, it do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4883d704cc9d395dd65e106906a1b22e
https://doi.org/10.1023/b:thro.0000024056.84909.b0
https://doi.org/10.1023/b:thro.0000024056.84909.b0
Publikováno v:
Journal of Thrombosis and Thrombolysis. 15:217-225
Angiotensin-converting enzyme inhibitors (ACE-I) were initially developed as therapeutic agents targeted for the treatment of hypertension. Since the initial application of these agents, several additional clinical indications have been identified su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7759baaa6b1ffd2cc7fc395e6f983c0
https://doi.org/10.1023/b:thro.0000011379.68077.64
https://doi.org/10.1023/b:thro.0000011379.68077.64
Publikováno v:
Journal of Thrombosis and Thrombolysis. 14:51-58
Differences in genetic makeup or polymorphisms can affect individual drug response. Detecting genetic variation may help predict how a patient will respond to a drug and could be used as a tool to select optimal therapy, tailor dosage regimens, and i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cc8e81a08be8e706fc86953a53ed681
https://doi.org/10.1023/a:1022066305399
https://doi.org/10.1023/a:1022066305399
Publikováno v:
Journal of Thrombosis and Thrombolysis. 13:49-56
Data regarding possible mechanisms of aspirin (ASA) resistance in patients with recurrent myocardial infarction (MI) or vascular ischemia are limited. Five major possible mechanisms of ASA resistance are documented in the primary literature and are d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::697041a2cf2c2a8ef197a0ccffb72bca
https://doi.org/10.1023/a:1015324310374
https://doi.org/10.1023/a:1015324310374